Cetuximab in Refractory Skin Cancer Treatment
<p><b>Objectives</b>: Non-melanoma skin cancer is the most common malignancy in US, with an annual incidence of in excess of 1.5 million cases. In the majority of cases, locoregional treatment is curative and systemic therapy is not indicated. Platinum-based chemotherapy regimens h...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ivyspring International Publisher
2012-01-01
|
| Series: | Journal of Cancer |
| Online Access: | http://www.jcancer.org/v03p0257.htm |